DXS INTERNATIONAL PLC
TRADING UPDATE
The Directors of DXS International plc, the developer and supplier of clinical decision support systems to Clinical Commissioning Groups and healthcare professionals are pleased to report that, following the trading update in February the Company has continued to make progress in line with management expectations.
Revenue continues to improve and it is anticipated that revenue for the year ending 30th April 2015 will be in excess of £2.6 million, an improvement of £200,000 on the anticipated figure announced in February, and 44 per cent ahead of the revenue for the year ending 30th April 2014.
The Company has also continued to sign new CCGs and has beaten the yearend target announced in February and has, at the end of May, signed 34 CCGs consisting of approximately 1,200 practices. The Company has also received Phase 1 Approval under the Common Assurance Process under GPSoC and is anticipating being able to move to new invoicing arrangements agreed with GPSoC in the very near future
The Company continues to have a healthy pipeline of new business and the Board remains confident that the business will continue to grow.
The Directors of DXS International plc accept responsibility for this announcement.
Contacts:
| David Immelman, CE0 DXS International plc www.dxs-systems.com | 01252 719800 |
| City & Merchant Ltd (Corporate Adviser) David Papworth | 020 7101 7676 |
| MB Communications (Financial PR) | |
| Maxine Barnes | 07860 489571 |
About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.